View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

WINFARM : Chiffre d’affaires du 3 è trimestre 2024.

WINFARM : Chiffre d’affaires du 3 è trimestre 2024. COMMUNIQUE DE PRESSE Loudéac, 7 novembre 2024 Chiffre d’affaires du 3è trimestre 2024 AgroFourniture : Poursuite du rattrapage des ventes malgré les récoltes tardives AgroProduction : Accélération de la forte croissance à deux chiffres des ventes WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chiffre d’affaires du 3è trimestre 2024 ...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Beneteau : Lower-than-expected Q3 sales. 2024 guidance confirmed. Redu...

>Q3 sales miss, down 38.6% to € 179.5m (€ 198.7m est) - Bénéteau reported Q3 sales of € 179.5m, 10% below our estimate of € 198.7m and 15% below the consensus (€ 210m). Q3 sales fell 38.6% vs Q3 2023 (after H1 sales were down 31.5%). Dealer destocking in Q3 accounted for -€ 30m (-€ 110m since the beginning of the year) which was consistent with the dealer destocking impact expected for the full year (-€ 100-150m). Over the first nine months of the year, sales came to ...

Christophe Chaput ... (+2)
  • Christophe Chaput
  • Hela Zarrouk

Bénéteau : CA T3 < aux attentes. Objectifs 2024 confirmés. Visibilité ...

>Un CA T3 inférieur aux attentes, en baisse de 38.6% à 179.5 M€ (198.7 M€e) - Au titre de son T3, le groupe Bénéteau publie un CA à 179.5 M€, inférieur à nos attentes puisque nous retenions 198.7 M€ (écart -10%) et également de celles du consensus (210 M€ ; écart -15%). Par rapport à l’année dernière, le CA T3 recule de 38.6% (après une baisse de -31.5% sur le S1). Sur le seul T3, le groupe subit un impact d’environ -30 M€ (-110 M€ depuis le début de l’année) lié à la...

 PRESS RELEASE

Pharming Group to participate in November investor conference

Pharming Group to participate in November investor conference Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November: Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharmin...

 PRESS RELEASE

WINFARM : Modalités de mise à disposition du Rapport Financier Semestr...

WINFARM : Modalités de mise à disposition du Rapport Financier Semestriel 2024. COMMUNIQUE DE PRESSE Loudéac, le 18 octobre 2024 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2024 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier semestriel 2024 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 18 octobre 2024. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disp...

 PRESS RELEASE

Pharming Group to report third quarter 2024 financial results on Octob...

Pharming Group to report third quarter 2024 financial results on October 24 Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial results, for the period ended September 30, on Thursday, October 24, 2024.Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on October 24, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique ...

 PRESS RELEASE

Pharming Group announces start of Phase II clinical trial of leniolisi...

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency and PTEN deficiency, with prevalence approximately five times that of APDS  Clinical trial being conducted at the National Institutes of Health (NIH) Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming” or “the Comp...

 PRESS RELEASE

WINFARM : Résultats semestriels 2024.

WINFARM : Résultats semestriels 2024. COMMUNIQUE DE PRESSE Loudéac, 3 octobre 2024 RESULTATS SEMESTRIELS 2024 Retour à la croissance au 2ème trimestre 2024Bonne tenue de la marge brute à 32,4% du chiffre d’affairesAtteinte d’un point bas de la rentabilité opérationnelle PERSPECTIVES S2 2024 Retour anticipé de la croissanceAmélioration de l’EBITDA intégrant le plein effet des mesures de relance de l’activité et d’encadrement des charges WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, publie aujourd’hui ses résultat...

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/26/2024

tonies is a pioneer in the children’s audio entertainment and educational industry, offering a screen-free and interactive listening experience (stories and music) through its Toniebox and Tonies figurines. With a proven track record of rapid international growth, portfolio expansion and strong brand recognition mainly in the DACH region (Germany, Austria and Switzerland) and North America, we see in the coming years: 1/ further strong revenue increases (CAGR 2024-2026e of 25%) with a...

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 26/09/2024

tonies is a pioneer in the children’s audio entertainment and educational industry, offering a screen-free and interactive listening experience (stories and music) through its Toniebox and Tonies figurines. With a proven track record of rapid international growth, portfolio expansion and strong brand recognition mainly in the DACH region (Germany, Austria and Switzerland) and North America, we see in the coming years: 1/ further strong revenue increases (CAGR 2024-2026e of 25%) with a...

Christophe Chaput
  • Christophe Chaput

Beneteau : H1 2024 results close to expectations

>H1 results close to expectations: Underlying operating profit of € 49.5m vs € 46.6m estimated - For H1 2024, the Bénéteau group reported results close to expectations (figures not including housing Habitat). Our takeaways are: 1/ A fall in EBITDA of 50.8% to € 77.7m which is in line with our estimates (€ 73.2m). 2/ A decline in operating profit of 62.3% to € 49.5m (€ 46.6m estimated) pointing to a deterioration in profitability of 720bp to 8.9%. This fall in underlyi...

Christophe Chaput
  • Christophe Chaput

Bénéteau : Des résultats S1 2024 proches des attentes

>Des résultats S1 proches des attentes : ROC 49.5 M€ vs 46.6 M€ estimé - Au titre de son premier semestre, le groupe Bénéteau publie des résultats proches des attentes (chiffres hors Habitat). Nous retenons ainsi : 1/ Une baisse de l’EBITDA de 50.8% à 77.7 M€ ce qui est cohérent avec nos propres estimations (73.2 M€). 2/ Une baisse du ROC de 62.3% à 49.5 M€ (46.6 M€ estimé) laissant apparaitre une dégradation de la profitabilité de 720 pb à 8.9%. Cette baisse du ROC s...

 PRESS RELEASE

Pharming announces marketing authorization in the U.K. for Joenja® (le...

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, September 26, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinosi...

 PRESS RELEASE

WINFARM : Croissance de +9,4% du chiffre d’affaires du T2 2024.

WINFARM : Croissance de +9,4% du chiffre d’affaires du T2 2024. COMMUNIQUE DE PRESSE Loudéac, le 4 septembre 2024 Croissance de +9,4% du chiffre d’affaires du T2 2024 AgroFourniture : Retour de la croissance AgroProduction : forte progression des ventes sur toutes les géographies WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chiffre d’affaires du 2ème trimestre 2024. En millions d’...

 PRESS RELEASE

Pharming Group to participate in September investor conferences

Pharming Group to participate in September investor conferences Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September: 2024 Wells Fargo Healthcare Conference, Boston, September 4-6Sijmen de Vries, Chief Executive Officer, will participate in a fireside chat question and answer session on Friday, September 6 at 08:45 AM ET/14:45 CET. A live webcast and replay of the presentation will be available i...

Pharming Group NV: 1 director

A director at Pharming Group NV sold 187,700 shares at 0.740EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

Pharming Group reports second quarter and first half 2024 financial re...

Pharming Group reports second quarter and first half 2024 financial results and provides business update Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 23% to US$63.0 million, compared to the second quarter 2023Joenja® (leniolisib) second quarter revenue increased by 16% to US$11.1 million, compared to the first quarter 2024 First half total revenues increased by 33% to US$129.7 million, compared to the first half 2023On track for 2...

Baptiste Salaville ... (+5)
  • Baptiste Salaville
  • Fehmi Ben Naamane
  • Jean-Baptiste Rouphael
  • Marc Lavaud
  • Oddo Sustainability Team

ODDO BHF Small & MIDCAP MORNING NEWS - 23/07/2024

Oerlikon, leader in attractive niche markets with technology entry barriers, is about to enter the final chapter of its group transition into a Surface Solutions pure play via the planned separation of Polymer Processing Solutions (OPP) in the next 12-36 months. After the strong performance YTD, we are seeing no further significant upside from here for now. We are rating Oerlikon’s shares Neutral with a TP of CHF 5.2.    - ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch